Evaxion Biotech A/S
NASDAQ:EVAX
Evaxion Biotech A/S
NASDAQ:EVAX
Price:
3.72 USD
-2.87%
Market Closed
Updated:
May 19, 2024
Evaxion Biotech A/S
Income from Continuing Operations
|
Evaxion Biotech A/S
Income from Continuing Operations Peer Comparison
Comparables:
GMAB
ZEAL
ASND
B
BAVA
BIOPOR
Competitive Income from Continuing Operations Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Evaxion Biotech A/S
NASDAQ:EVAX
|
Income from Continuing Operations
-$22.1m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Genmab A/S
CSE:GMAB
|
Income from Continuing Operations
kr5.5B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
32%
|
CAGR 10-Years
44%
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Income from Continuing Operations
-kr703.7m
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-14%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Income from Continuing Operations
-€501.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Income from Continuing Operations
kr984.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Income from Continuing Operations
-kr53.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-10%
|
See Also
What is Evaxion Biotech A/S's Income from Continuing Operations?
Income from Continuing Operations
-22.1m
USD
-22.1m
USD
Based on the financial report for Dec 31, 2023, Evaxion Biotech A/S's Income from Continuing Operations amounts to -22.1m USD.
What is Evaxion Biotech A/S's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 5Y
-32%
-32%
Over the last year, the Income from Continuing Operations growth was 5%. The average annual Income from Continuing Operations growth rates for Evaxion Biotech A/S have been -14% over the past three years , -32% over the past five years .
You don't have any saved screeners yet
